Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: Relevance to in vivo prediction

European Journal of Pharmaceutical Sciences

Volumn 26, Issue 5, 2005, Pages 386-393

  Collett, Andrew ^a   Tanianis Hughes, Jola ^a   Carlson, Gordon L ^a   Harwood, Matthew D ^a   Warhurst, Geoff ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Caco 2; Digoxin; Drug drug interactions; Human; P glycoprotein; Prediction

Indexed keywords

CYCLOSPORIN; DIGOXIN; GLYCOPROTEIN P; OMEPRAZOLE; QUINIDINE; TALINOLOL; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG PENETRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RODENT;

ANIMALS; CACO-2 CELLS; DIGOXIN; DRUG INTERACTIONS; HUMANS; INTESTINES; MALE; MICE; OMEPRAZOLE; P-GLYCOPROTEIN;

EID: 27644521247     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.07.013     Document Type: Article

References (32)

1. Y. Adachi, H. Suzuki, and Y. Sugiyama Comparative studies of in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein Pharm. Res. 18 2001 1660 1668
2. A. Aszalos P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations Arch. Pharm. Res. 27 2004 127 135
3. L.Z. Benet, C.L. Cummins, and C.Y. Wu Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data Curr. Drug Metab. 4 2003 393 398
4. A. Collett, J. Tanianis-Hughes, D. Hallifax, and G. Warhurst Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo Pharm. Res. 21 2004 819 826
5. S. Drescher, H. Glaeser, T. Murdter, M. Hitzl, M. Eichelbaum, and M.F. Fromm P-glycoprotein-mediated intestinal and biliary digoxin transport in humans Clin. Pharmacol. Ther. 73 2003 223 231
6. M. Eichelbaum, M.F. Fromm, and M. Schwab Clinical aspects of the MDR1 (ABCB1) gene polymorphism Ther. Drug Monit. 26 2004 180 185
7. G. Englund, P. Hallberg, P. Artursson, K. Michaelsson, and H. Melhus Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring BMC Med. 2 1 2004 8
8. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, and D.M. Roden Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
9. J. Gao, O. Murase, R.L. Schowen, J. Aube, and R.T. Borchardt A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells Pharm. Res. 18 2001 171 176
10. W.D. Hager, M. Mayersohn, and P.E. Graves Digoxin bioavailability during quinidine administration Clin. Pharmacol. Ther. 30 1981 594 599
11. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc. Natl. Acad. Sci. U.S.A. 97 2000 3473 3478
12. P.M. Hooymans, and F.W. Merkus Current status of cardiac glycoside drug interactions Clin. Pharm. 4 1985 404 413
13. C.S. Karyekar, N.D. Eddington, T.S. Garimella, P.O. Gubbins, and T.C. Dowling Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model Pharmacotherapy 23 2003 436 442
14. G.A. Kulla-Ublick, and M.B. Becker Regulation of drug and bile salt transporters in liver and intestine Drug Metab. Rev. 35 2003 305 317
15. H. Kusuhara, and Y. Sugiyama Role of transporters in the tissue-selective distribution and elimination of drugs J. Contr. Release 78 2002 43 54
16. J.L. Lam, and L.Z. Benet Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes Drug Metab. Dispos. 32 2004 1311 1316
17. J. Lill, L.A. Bauer, J.R. Horn, and P.D. Hansten Cyclosporine-drug interactions and the influence of patient age Am. J. Health Syst. Pharm. 57 2000 1579 1584
18. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug Delivery Rev. 55 2003 53 81
19. N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of drug transporter studies on drug discovery and development Pharmacol. Rev. 55 2003 425 461
20. P.J. Neuvonen, K. Kivisto, and E.L. Hirvisalo Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide Br. J. Clin. Pharmacol. 25 1988 229 233
21. B. Oosterhuis, J.H. Jonkman, T. Andersson, P.B. Zuiderwijk, and J.N. Jedema Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose Br. J. Clin. Pharmacol. 32 1991 569 572
22. M.D. Perloff, L.L. von Moltke, and D.J. Greenblatt Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir J. Clin. Pharmacol. 42 2002 1269 1274
23. J.W. Polli, J.L. Jarrett, S.D. Studenberg, J.E. Humphreys, S.W. Dennis, K.R. Brouwer, and J.L. Woolley Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor Pharm. Res. 16 1999 1206 1212
24. S.M. Rodin, B.F. Johnson, J. Wilson, P. Ritchie, and J. Johnson Comparative effects of verapamil and isradipine on steady-state digoxin kinetics Clin. Pharmacol. Ther. 43 1988 668 672
25. U.I. Schwarz, T. Gramatte, J. Krappweis, R. Oertel, and W. Kirch P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int. J. Clin. Pharmacol. Ther. 38 2000 161 167
26. R.H. Stephens, C.A. O'Neill, J. Bennett, M. Humphrey, B. Henry, M. Rowland, and G. Warhurst Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a(-/-) mice Br. J. Pharmacol. 135 2002 2038 2046
27. R.H. Stephens, C.A. O'Neill, A. Warhurst, G.L. Carlson, M. Rowland, and G. Warhurst Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J. Pharmacol. Exp. Ther. 296 2001 584 591
28. J. Taipalensuu, H. Tornblom, G. Lindberg, C. Einarsson, F. Sjoqvist, H. Melhus, P. Garberg, B. Sjostrom, B. Lundgren, and P. Artursson Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers J. Pharmacol. Exp. Ther. 299 2001 164 170
29. G. Warhurst, N.B. Higgs, H. Fakhoury, A.C. Warhurst, J. Garde, and D.H. Coy Somatostatin receptor subtype 2 mediates somatostatin inhibition of ion secretion in rat distal colon Gastroenterology 111 1996 325 333
30. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche, R. Oertel, B. Terhaag, H.K. Kroemer, and W. Siegmund Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein Clin. Pharmacol. Ther. 68 2000 6 12
31. C. Woodland, G. Koren, and S. Ito From bench to bedside: utilisation of an in vitro model to predict potential drug-drug interactions in the kidney J. Clin. Pharmacol. 43 2003 743 750
32. Y. Zhang, C. Bachmeier, and D.W. Miller in vitro and in vivo models for assessing drug efflux transporter activity Adv. Drug Delivery Rev. 55 2003 31 51